# Alnylam Pharmaceuticals, Inc.  Share Price Target ‘$219.48’, now 32.5% Upside Potential

- Link: https://www.directorstalkinterviews.com/alnylam-pharmaceuticals-inc.share-price-target-219.48-now-32.5-upside-potential/4121162135
- Published: 2024-06-25T13:42:36+01:00
- Author: Charlotte Edwards

**Alnylam Pharmaceuticals, Inc.** which can be found using ticker (ALNY) now have
24 market analysts covering the stock. The analyst consensus now points to a rating
of ‘buy’. The range between the high target price and low target price is between
$400.00 and $138.00 with the average share target price sitting at $219.48. (at 
the time of writing). Now with the previous closing price of $165.70 this would 
indicate that there is a potential upside of 32.5%. The 50 day MA is $151.88 and
the 200 day moving average is $165.18. The company has a market cap of 28.20B. The
stock price is currently at: $222.90 USD

 The potential market cap would be $37,346,125,854 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $15.97 and
a -3.05% return on assets.

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The
Company is engaged in developing therapeutics based on ribonucleic acid interference(
RNAi). Its pipeline includes five marketed products and over ten clinical programs,
including several in late-stage development, across four strategic therapeutic areas(
STArs): genetic medicines, cardio-metabolic diseases, hepatic infectious diseases,
and CNS/ocular diseases. Its RNAi-based medicines include ONPATTRO (patisiran), 
AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran).
ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin
amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase
1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease
manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting
hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1.

Share on: